Following rumors that both Samsung Bioepis and Intas were interested in a bid for Biogen’s biosimilars business, Dr Reddy’s has become the latest firm to be named in media reports as a potential buyer.
With reports naming the Indian generics giant as joining the race to acquire the biosimilars business – valuing a possible...





